Clinical trials: CGM
Type 1 Diabetes
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study
Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator…
- Trial name
- NCT04320069
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT03966911
- Testing
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Where
- 15 sites in United States
- Volunteers
- 335 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
Assessing Non-adjunctive CGM Safety at Home and in New Markets
The purpose of the study is to examine whether non-adjunctive (without having to double check using another method) use of Continuous Glucose Monitoring improves A1c in adults or children with diabetes managed by intensive…
- Trial name
- ANSHIN (NCT04585139)
- Testing
- Phase 1- Introduction to Dexcom G6 CGM
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- DexCom, Inc.
Diabetes
Diabetes Multicenter Observational Study (DIAMOND-1-)
The purpose of this study is to examine whether pump treatment combined with the use of continuous glucose monitoring system is a mena to normalize glycaemic control.
- Trial name
- DIAMOND-1 (NCT01369823)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medtronic Hellas Medical Devices ΑEE
T1DM - Type 1 Diabetes Mellitus
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
- Trial name
- NCT05908448
- Testing
- 13 CGM (continuous glucose monitor)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Sinocare
Quality of Life, Burden, Dependency
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life
The use by diabetes patients of real-time Continuous Glucose Monitoring (CGM) system is becoming widespread and has changed diabetic practice. Automated closed-loop (CL) insulin therapy has come of age.
- Trial name
- IMPLIQUE (NCT04939766)
- Testing
- Activation of a closed loop device in an insulin pump device with GCM
- Volunteers
- 250 people
- Sponsor
- VitalAire
Type 1 Diabetes
A Performance Evaluation of the Enlite 3 Sensor
The purpose of this study is to support the use of the Enlite 3 sensor in arm and thigh in subjects age 14 - 75 years and provide additional characterization of the Enlite 3 sensor performance in arm in subjects age 14 - 75 years.
- Trial name
- NCT02649010
- Testing
- Enlite 3 Sensor
- Where
- 2 sites in United States
- Sponsor
- Medtronic MiniMed, Inc.
Glycogen Storage Disease Type IA
Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa
The primary objective of this study is to assess the percentage of time patients were in normal glucose control.
- Trial name
- NCT04708015
- Testing
- No Intervention
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 15 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Diabetes
Continuous Monitoring and Control of Hypoglycemia
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
- Trial name
- COACH (NCT03340831)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- 25 sites in United States
- Volunteers
- 1,388 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm…
- Trial name
- STAR1 (NCT00211510)
- Testing
- Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
FreeStyle Libre Continuous Glucose Monitoring System Accuracy Study
The purpose of this study is to characterize the Freestyle Libre Glucose Monitoring System in pediatric and adult subjects with respect to YSI reference venous plasma sample measurements.
- Trial name
- NCT04464772
- Testing
- FreeStyle Libre 3
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus, Diabetes Mellitus, Type 1
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
A Prospective, Multicenter Evaluation of Accuracy and Safety of the Eversense CGM System with Enhanced Features. The purpose of this clinical investigation is to evaluate the accuracy of the Eversense 524 Continuous Glucose…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT05131139
- Testing
- Continuous Glucose Monitoring System
- Where
- 4 sites in United States
- Volunteers
- 350 people
- Sponsor
- Senseonics, Inc.
Diabetes
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
- Trial name
- NCT06483945
- Testing
- Dexcom CGM G6/G6 Pro/G7
- Where
- 2 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- DexCom, Inc.
Diabetes Mellitus
A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System in Canada
The purpose of this clinical investigation is to evaluate the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System.
- Trial name
- NCT02933164
- Testing
- Continuous Glucose Monitoring System
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus, Type 2
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes.
- Trial name
- ACHIEVE-PEDS (NCT07668336)
- Testing
- Orforglipron, Dulaglutide
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 170 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
- Trial name
- SUCCEED2 (NCT06604871)
- Testing
- Insulin Pump with Continuous Glucose Monitoring
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
- Trial name
- NCT04794478
- Testing
- Dexcom Continuous Glucose Monitoring System
- Where
- 12 sites in United States
- Volunteers
- 482 people
- Sponsor
- DexCom, Inc.
Diabetes
Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)
Global Registry study
- Trial name
- NCT07681024
- Testing
- Dexcom CGM (Continuous Glucose Monitor)
- Volunteers
- 5,000 people
- Sponsor
- DexCom, Inc.
Diabetes Mellitus
Effectiveness and Safety of the Dexcom™ G6 Continuous Glucose Monitoring System
Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring (CGM) System
- Trial name
- NCT02880267
- Testing
- CGM
- Where
- 9 sites in United States
- Volunteers
- 304 people
- Sponsor
- DexCom, Inc.
Diabetes Mellitus
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate the safety and effectiveness of the G4 System when worn for up to 7-days by children and adolescent subjects (6 to <18 years-old) with type 1 diabetes mellitus.
- Trial name
- NCT01185496
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- DexCom, Inc.